Kenvue (KVUE)
Market Price (4/30/2026): $17.12 | Market Cap: $32.8 BilSector: Consumer Staples | Industry: Personal Care Products
Kenvue (KVUE)
Market Price (4/30/2026): $17.12Market Cap: $32.8 BilSector: Consumer StaplesIndustry: Personal Care Products
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.2%, Dividend Yield is 4.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.4%, FCF Yield is 5.2% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 18% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%, CFO LTM is 2.2 Bil Low stock price volatilityVol 12M is 33% Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Nutritional Supplements, Organic & Natural Products, Show more. | Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -102% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4% Key risksKVUE key risks include [1] significant legal liabilities from litigation over its Tylenol, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.2%, Dividend Yield is 4.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.4%, FCF Yield is 5.2% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 18% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%, CFO LTM is 2.2 Bil |
| Low stock price volatilityVol 12M is 33% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Nutritional Supplements, Organic & Natural Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -102% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4% |
| Key risksKVUE key risks include [1] significant legal liabilities from litigation over its Tylenol, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Kenvue (KVUE) stock has remained largely at the same level since 12/31/2025 because of the following key factors:
1. Pending Acquisition by Kimberly-Clark Provided a Price Anchor.
The definitive merger agreement, overwhelmingly approved by Kenvue and Kimberly-Clark shareholders on January 29, 2026, for Kimberly-Clark to acquire Kenvue at approximately $21.01 per share (based on Kimberly-Clark's closing price on October 31, 2025), has largely constrained Kenvue's stock movement. This fixed deal value, with the transaction expected to close in the second half of 2026, has likely limited significant independent upward price fluctuations as the market prices in the acquisition.
2. Better-than-Expected Q4 2025 Earnings Provided Fundamental Support.
Kenvue reported robust fourth-quarter 2025 financial results on February 17, 2026, with earnings per share (EPS) of $0.27, exceeding analyst estimates of $0.22 by $0.05 (a 22.73% beat). Quarterly revenue also surpassed expectations, reaching $3.78 billion against estimates of $3.68 billion, marking a 3.2% year-over-year increase. This positive earnings surprise likely provided a floor for the stock, preventing a downward trend despite some post-earnings drift.
Show more
1. Pending Acquisition by Kimberly-Clark Provided a Price Anchor.
The definitive merger agreement, overwhelmingly approved by Kenvue and Kimberly-Clark shareholders on January 29, 2026, for Kimberly-Clark to acquire Kenvue at approximately $21.01 per share (based on Kimberly-Clark's closing price on October 31, 2025), has largely constrained Kenvue's stock movement. This fixed deal value, with the transaction expected to close in the second half of 2026, has likely limited significant independent upward price fluctuations as the market prices in the acquisition.
2. Better-than-Expected Q4 2025 Earnings Provided Fundamental Support.
Kenvue reported robust fourth-quarter 2025 financial results on February 17, 2026, with earnings per share (EPS) of $0.27, exceeding analyst estimates of $0.22 by $0.05 (a 22.73% beat). Quarterly revenue also surpassed expectations, reaching $3.78 billion against estimates of $3.68 billion, marking a 3.2% year-over-year increase. This positive earnings surprise likely provided a floor for the stock, preventing a downward trend despite some post-earnings drift.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 1.0% change in KVUE stock from 12/31/2025 to 4/29/2026 was primarily driven by a 1.8% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 4292026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.05 | 17.23 | 1.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 15,006 | 15,124 | 0.8% |
| Net Income Margin (%) | 9.5% | 9.7% | 1.8% |
| P/E Multiple | 22.8 | 22.5 | -1.6% |
| Shares Outstanding (Mil) | 1,918 | 1,917 | 0.1% |
| Cumulative Contribution | 1.0% |
Market Drivers
12/31/2025 to 4/29/2026| Return | Correlation | |
|---|---|---|
| KVUE | 1.0% | |
| Market (SPY) | 5.2% | 12.2% |
| Sector (XLP) | 7.3% | 57.0% |
Fundamental Drivers
The 8.7% change in KVUE stock from 9/30/2025 to 4/29/2026 was primarily driven by a 4.8% change in the company's P/E Multiple.| (LTM values as of) | 9302025 | 4292026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.85 | 17.23 | 8.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 15,141 | 15,124 | -0.1% |
| Net Income Margin (%) | 9.4% | 9.7% | 3.8% |
| P/E Multiple | 21.4 | 22.5 | 4.8% |
| Shares Outstanding (Mil) | 1,919 | 1,917 | 0.1% |
| Cumulative Contribution | 8.7% |
Market Drivers
9/30/2025 to 4/29/2026| Return | Correlation | |
|---|---|---|
| KVUE | 8.7% | |
| Market (SPY) | 8.0% | 9.7% |
| Sector (XLP) | 7.3% | 37.1% |
Fundamental Drivers
The -25.1% change in KVUE stock from 3/31/2025 to 4/29/2026 was primarily driven by a -47.4% change in the company's P/E Multiple.| (LTM values as of) | 3312025 | 4292026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.99 | 17.23 | -25.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 15,455 | 15,124 | -2.1% |
| Net Income Margin (%) | 6.7% | 9.7% | 45.8% |
| P/E Multiple | 42.7 | 22.5 | -47.4% |
| Shares Outstanding (Mil) | 1,915 | 1,917 | -0.1% |
| Cumulative Contribution | -25.1% |
Market Drivers
3/31/2025 to 4/29/2026| Return | Correlation | |
|---|---|---|
| KVUE | -25.1% | |
| Market (SPY) | 29.3% | 17.6% |
| Sector (XLP) | 4.3% | 44.2% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2023 to 4/29/2026| Return | Correlation | |
|---|---|---|
| KVUE | ||
| Market (SPY) | 81.5% | 15.7% |
| Sector (XLP) | 20.4% | 44.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| KVUE Return | - | - | -19% | 3% | -16% | 3% | -28% |
| Peers Return | 18% | -13% | -5% | 2% | -4% | 1% | -4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 90% |
Monthly Win Rates [3] | |||||||
| KVUE Win Rate | - | - | 38% | 50% | 42% | 75% | |
| Peers Win Rate | 57% | 40% | 47% | 60% | 35% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| KVUE Max Drawdown | - | - | -32% | -16% | -32% | -3% | |
| Peers Max Drawdown | -10% | -28% | -18% | -12% | -21% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PG, CL, CHD, KMB, EL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/29/2026 (YTD)
How Low Can It Go
null
nullIn The Past
null
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Kenvue (KVUE)
We are the world’s largest pure-play consumer health company by revenue with $15.0 billion in net sales in 2022. We combine the power of science with meaningful human insights and digital-first capabilities, which we believe empowers approximately 1.2 billion people to live healthier lives every day. Our differentiated portfolio of iconic brands—including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec and Nicorette—is built for moments that uniquely matter to our consumers and, we believe, drives positive health outcomes around the world. We are a global leader at the intersection of healthcare and consumer goods, with a portfolio of iconic brands, operating in some of the most attractive categories in consumer health from both a growth and profitability perspective. Our consumer health portfolio includes self care, skin care and beauty and essential personal care products, which reflect categories that we believe allow consumers across the world to realize the extraordinary power of everyday care. We hold leadership positions across a $369 billion consumer health market that we expect to grow at a compounded annual growth rate (“CAGR”) of 3% to 4% globally through 2025. We are well positioned to capitalize on this large market opportunity through our holistic approach to delivering consumer health solutions. This approach starts with our distinctive understanding of various consumer needs, which allows us to apply our consumer insights across multiple categories and brands. These comprehensive solutions are backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands. Our portfolio of brands is widely recognized and represents a combination of global and regional brands, many of which hold leading positions in their respective categories. Ten of our brands had approximately $400 million or more in net sales in 2022, and we currently hold seven #1 brand positions across major categories globally, in addition to many #1 brand positions locally across our four regions. In 2022, our net sales were well balanced and scaled across three segments: Self Care (40%), Skin Health and Beauty (29%) and Essential Health (31%). --- Our global footprint is also well balanced geographically with approximately half of our net sales generated outside North America in 2022. The breadth and scale of our portfolio allows us to dynamically capitalize on and respond to current trends impacting our categories and geographic markets. Our breadth and scale also provide us with a strong platform to broaden and enhance our portfolio in the future. Our global scale and brand portfolio are complemented by our well-developed capabilities and accelerated through our digital-first approach, allowing us to deliver better consumer health experiences. Our marketing organization leverages our e-commerce, precision marketing and broader digital capabilities to develop unique consumer insights and further enhance the relevance of our brands. Our research and development (“R&D”) organization leverages these consumer insights and places human empathy at the heart of our product development process. We combine that perspective with deep, multi-disciplinary scientific expertise, and engagement with healthcare professionals, to drive innovative new products, solutions and experiences. Our marketing and innovation capabilities are further complemented by our end-to-end, digitally connected supply chain ecosystem which is designed to optimize the flexibility and agility of our route-to-market. Our sourcing, manufacturing and demand planning capabilities are continuously optimized to meet evolving market dynamics. We also aim to leverage our flexible distribution network, consumer health thought leadership and data-driven customer partnerships to continue to drive joint value creation for us and our retail customers. Underpinned by our comprehensive environmental, social and governance (“ESG”) strategy, our core capabilities are supported by our commitment to building a resilient and sustainable business that creates value for all our stakeholders over the long term. The strength of our business has created a compelling financial profile characterized by net sales growth and strong profitability. We were incorporated in Delaware on February 23, 2022 in connection with the Separation and were formed to ultimately hold, directly or indirectly, and conduct certain operational activities in anticipation of the planned separation of, the Consumer Health Business. Prior to the completion of this offering, we are a wholly owned subsidiary of Johnson & Johnson. Our principal executive offices are located at 199 Grandview Road, Skillman, NJ.
AI Analysis | Feedback
Kenvue is like the Procter & Gamble for health and personal care brands.
AI Analysis | Feedback
- Tylenol: Over-the-counter medication for pain relief and fever reduction.
- Neutrogena: A range of skincare, haircare, and cosmetics products.
- Listerine: Oral care products, primarily antiseptic mouthwash.
- Johnson's: A line of baby care and personal care products.
- Band-Aid: Brand of adhesive bandages and wound care products.
- Aveeno: Skincare and body care products, often focused on natural ingredients.
- Zyrtec: Over-the-counter medication for allergy relief.
- Nicorette: Products designed to help individuals quit smoking, primarily nicotine replacement therapy.
AI Analysis | Feedback
Kenvue (KVUE) sells primarily to other companies, specifically various retail organizations. The company's portfolio of iconic brands, including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec, and Nicorette, are made available to individual consumers through these retail channels.
While the background information confirms that Kenvue engages in "data-driven customer partnerships" with its "retail customers," it does not list the specific names of these major customer companies or their public symbols. Therefore, specific customer company names cannot be provided from the given text.
AI Analysis | Feedback
nullAI Analysis | Feedback
Kenvue (KVUE) has a leadership team comprising experienced professionals in the consumer health industry. Kirk Perry Chief Executive Officer and Director Kirk Perry was appointed as the interim Chief Executive Officer of Kenvue in July 2025 and subsequently as the permanent CEO in November 2025. He also serves as a Director on the Board. Mr. Perry brings over 30 years of global consumer-packaged goods, technology, and business transformation experience. Prior to joining Kenvue's Board of Directors in December 2024, he was the President and Chief Executive Officer of Circana, a global provider of technology, data, and predictive analytics for the consumer, retail, and media sectors. He continues to serve on the Circana board. Before Circana, Mr. Perry worked at Procter & Gamble for 23 years. Amit Banati Chief Financial Officer Amit Banati became the Chief Financial Officer of Kenvue on May 12, 2025. In this role, he is responsible for overseeing the finance and strategy functions, supporting initiatives for profitable growth, and delivering shareholder value. Mr. Banati is a veteran in consumer products company finance and operations, with 30 years of experience. He previously served as Vice Chairman and Chief Financial Officer of Kellanova (formerly Kellogg Company), where he oversaw financial operations, strategic planning, and M&A, including a venture capital fund. His career also includes finance and operating leadership roles at Kraft Foods (now Mondelez International), Cadbury Schweppes, and Procter & Gamble. He has extensive international experience, having overseen operations in regions like Asia Pacific, the Middle East, India, and Africa. Mr. Banati is also a Non-Executive Director at Fortune Brands Innovations. Caroline Tillett, PhD Chief Scientific Officer Dr. Caroline Tillett is the Chief Scientific Officer for Kenvue and a member of the Kenvue Leadership Team since May 2023. She leads the company's Research & Development organization, including new product and packaging development, sustainability, medical safety, and regulatory affairs, driving innovation across Self Care, Skin Health & Beauty, and Essential Health segments. With over 20 years of experience in consumer health, Dr. Tillett previously served as Global Head, R&D, for Johnson & Johnson Consumer Health. Before joining Johnson & Johnson, she was interim Global Head of Consumer R&D at GSK and was the R&D leader for the GSK/Novartis joint venture, which resulted in the formation of an $8 billion consumer health company. She also served on the leadership team that created the GSK/Pfizer Consumer Healthcare joint venture. She holds a B.Sc. in Applied Chemistry and a Ph.D. in Organic Chemistry from Kingston University (UK). Luani Alvarado Chief People Officer Luani Alvarado serves as the Chief People Officer for Kenvue. In this role, she is responsible for leading the company's talent strategy, overseeing People Experience, Inclusion, Talent Development, Compensation, Health & Well-Being, HR Business Partners, and Operations. She previously served as Global Leader, Human Resources, Johnson & Johnson Consumer Health. Ms. Alvarado has over 15 years of experience at Johnson & Johnson, holding various leadership positions including Global Head of HR for Ethicon, Enterprise Chief Talent Officer, Head of HR for Global Orthopaedics, Global Head of HR for Medical Devices, and Global Head of HR for External Innovation. Prior to her time at Johnson & Johnson, she spent eight years at Bristol-Myers Squibb in Human Resources, working internationally across Pharmaceuticals, Consumer, and Devices. She began her career at Dow Chemical. Matt Orlando General Counsel Matt Orlando is the General Counsel for Kenvue and a member of the Kenvue Leadership Team since May 2023. He leads the Legal, Compliance, Privacy, Global Security, and Brand Protection organizations. Mr. Orlando previously served as Corporate Secretary and Worldwide Vice President, Corporate Governance, for Johnson & Johnson, acting as a liaison to the Johnson & Johnson Board of Directors and the investment community. During his more than 15 years with Johnson & Johnson, he held various legal leadership roles, including General Counsel, Global Consumer Medical Devices. His legal experience spans Australia, Europe, and the United States. Before joining Johnson & Johnson, Mr. Orlando worked for the pharmaceutical company UCB in Brussels and for law firms in Australia. He holds a law degree and a finance degree from Murdoch University in Australia and is admitted to practice law in both the United States and Australia.AI Analysis | Feedback
-
Kenvue faces risks associated with its separation from Johnson & Johnson, as it was incorporated in connection with the separation and was a wholly-owned subsidiary of Johnson & Johnson prior to its offering. This transition may involve challenges in establishing independent operations, systems, and supply chains, and could lead to the loss of benefits previously derived from being part of a larger, diversified parent company.
-
The company operates in a highly competitive global consumer health market, which is expected to grow at a compounded annual growth rate of 3% to 4% globally through 2025. Maintaining leadership positions and adapting to evolving consumer preferences in this dynamic and large market, valued at $369 billion, requires continuous innovation, effective marketing, and strategic responses to competitive pressures.
-
Kenvue's business is significantly dependent on a concentrated portfolio of iconic brands, with ten of its brands generating approximately $400 million or more in net sales in 2022, and holding seven #1 brand positions across major categories globally. While a strength, this concentration means that any adverse events affecting these key brands, such as product recalls, reputational damage, or increased competition, could have a disproportionately significant impact on the company's financial performance.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlKenvue operates within a global consumer health market with an addressable size of $369 billion. This market is expected to grow at a compounded annual growth rate of 3% to 4% globally through 2025.
```AI Analysis | Feedback
Kenvue (KVUE) anticipates several key drivers for its future revenue growth over the next 2-3 years:
- Value Realization through Pricing and Mix Management: The company expects to drive organic sales growth through a combination of strategic pricing adjustments and optimizing its product mix towards higher-value offerings. This "value realization" has been a consistent component of its organic sales growth outlook.
- Increased Brand Investments and Marketing: Kenvue is actively increasing its investments in brand marketing, including engagement with healthcare professionals and direct consumer initiatives, to bolster brand strength and fuel growth. This strategy aims to enhance consumer connection and drive demand for its portfolio of iconic brands.
- Supply Chain Efficiency and Productivity Gains: Improvements in supply chain efficiency and broader productivity initiatives are expected to contribute to adjusted gross profit margin expansion. These operational enhancements can indirectly support revenue growth by allowing for strategic investments in the business or by enabling competitive pricing.
- Strong Performance in the Essential Health Segment: The Essential Health segment has consistently shown robust organic growth across various categories and geographical regions. This segment is expected to continue to be a significant contributor to Kenvue's overall revenue expansion.
- Operational Transformation and Exit from Transition Service Agreements (TSAs): Kenvue's ongoing efforts to improve productivity, reduce costs, and fully exit Transition Service Agreements (TSAs) are designed to enhance operational focus and free up resources. This greater autonomy and efficiency are aimed at supporting core growth strategies.
AI Analysis | Feedback
Share Repurchases
- Kenvue's stated capital allocation priorities include share buybacks to offset dilution.
- The company did not make any share buybacks in the fourth quarter of 2025.
Share Issuance
- Kenvue completed its Initial Public Offering (IPO) in May 2023, raising $3.8 billion.
- During the IPO, Kenvue offered 198.7 million shares at $22.00 per share, including the underwriters' full exercise of their over-allotment option.
- Johnson & Johnson completed the disposition of an additional 80.1% of Kenvue's outstanding common stock in August 2023, transitioning Kenvue to a fully independent public company.
Capital Expenditures
- Kenvue's capital expenditures were $0.4 billion in 2024 and increased to $0.5 billion in 2025.
- The company initiated the "Our Vue Forward" program, incurring approximately $550 million in restructuring costs split between 2024 and 2025, to optimize its geographic footprint, reduce redundancies, and implement new systems.
- Capital investments are directed towards areas such as innovation, research and development (R&D), and enhancing its digitally connected supply chain ecosystem.
Latest Trefis Analyses
Trade Ideas
Select ideas related to KVUE.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03272026 | MZTI | Marzetti | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.9% | 0.9% | 0.0% |
| 03272026 | TAP | Molson Coors Beverage | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -0.8% | -0.8% | -1.1% |
| 03202026 | KHC | Kraft Heinz | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.3% | 4.3% | -1.7% |
| 03202026 | KMB | Kimberly-Clark | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -1.8% | -1.8% | -1.9% |
| 03202026 | MKC | McCormick | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -5.2% | -5.2% | -5.2% |
| 12192025 | KVUE | Kenvue | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 2.5% | 2.5% | -1.6% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 90.29 |
| Mkt Cap | 32.5 |
| Rev LTM | 15,840 |
| Op Inc LTM | 2,594 |
| FCF LTM | 1,780 |
| FCF 3Y Avg | 2,099 |
| CFO LTM | 2,696 |
| CFO 3Y Avg | 2,803 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.8% |
| Rev Chg 3Y Avg | 1.4% |
| Rev Chg Q | 4.8% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Inc Chg LTM | -3.5% |
| Op Inc Chg 3Y Avg | 1.5% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 17.6% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 19.4% |
| CFO/Rev 3Y Avg | 19.0% |
| FCF/Rev LTM | 14.4% |
| FCF/Rev 3Y Avg | 14.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 32.5 |
| P/S | 2.8 |
| P/Op Inc | 16.5 |
| P/EBIT | 18.0 |
| P/E | 21.5 |
| P/CFO | 16.3 |
| Total Yield | 5.3% |
| Dividend Yield | 2.0% |
| FCF Yield 3Y Avg | 4.6% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.0% |
| 3M Rtn | 0.1% |
| 6M Rtn | 6.4% |
| 12M Rtn | -6.7% |
| 3Y Rtn | -12.1% |
| 1M Excs Rtn | -11.5% |
| 3M Excs Rtn | -2.2% |
| 6M Excs Rtn | 0.1% |
| 12M Excs Rtn | -34.9% |
| 3Y Excs Rtn | -84.0% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Self Care | 6,527 | 6,451 | 6,030 | 5,643 | 5,235 |
| Essential Health | 4,688 | 4,615 | 4,570 | 4,870 | 4,782 |
| Skin Health and Beauty | 4,240 | 4,378 | 4,350 | 4,541 | 4,450 |
| Total | 15,455 | 15,444 | 14,950 | 15,054 | 14,467 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Self Care | 2,173 | 2,299 | 2,088 | 1,952 | 1,702 |
| Essential Health | 1,162 | 1,011 | 1,111 | 1,224 | 1,014 |
| Skin Health and Beauty | 607 | 679 | 708 | 878 | 1,281 |
| Proposed Transaction costs | 0 | ||||
| Other operating expense (income), net | -26 | 10 | 23 | -15 | -3,871 |
| Founder Shares | -29 | -9 | 0 | 0 | |
| Conversion of stock-based awards | -39 | -55 | 0 | 0 | |
| Restructuring and operating model optimization initiatives | -221 | -32 | -100 | -116 | |
| Amortization of intangible assets | -269 | -322 | -348 | -414 | |
| Separation-related costs | -296 | -468 | -213 | 0 | |
| General corporate/unallocated expenses | -314 | -296 | -298 | -272 | -277 |
| Depreciation | -329 | -305 | -296 | -317 | |
| Impairment charges | -578 | 0 | |||
| Depreciation and amortization | -746 | ||||
| Restructuring expense | -82 | ||||
| Total | 1,841 | 2,512 | 2,675 | 2,920 | -979 |
Price Behavior
Price Behavior
| Market Price | $17.23 | |
| Market Cap ($ Bil) | 33.0 | |
| First Trading Date | 05/04/2023 | |
| Distance from 52W High | -26.5% | |
| 50 Days | 200 Days | |
| DMA Price | $17.78 | $17.72 |
| DMA Trend | down | indeterminate |
| Distance from DMA | -3.1% | -2.7% |
| 3M | 1YR | |
| Volatility | 20.5% | 33.0% |
| Downside Capture | 0.16 | 0.32 |
| Upside Capture | 23.18 | 10.19 |
| Correlation (SPY) | 25.9% | 9.4% |
KVUE Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.45 | 0.21 | -0.05 | 0.16 | 0.30 | -0.09 |
| Up Beta | 1.37 | 0.40 | -0.10 | -0.48 | 0.13 | 0.10 |
| Down Beta | -0.07 | 0.49 | 0.05 | 0.25 | 0.40 | 0.20 |
| Up Capture | 24% | 25% | 1% | 37% | 14% | 7% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 24 | 34 | 63 | 123 | 341 |
| Down Capture | 90% | -3% | -16% | 16% | 67% | 69% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 13 | 17 | 28 | 60 | 125 | 370 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KVUE | |
|---|---|---|---|---|
| KVUE | -22.3% | 33.0% | -0.72 | - |
| Sector ETF (XLP) | 5.8% | 12.5% | 0.17 | 39.7% |
| Equity (SPY) | 31.5% | 12.5% | 1.93 | 9.6% |
| Gold (GLD) | 35.2% | 27.2% | 1.09 | -1.4% |
| Commodities (DBC) | 46.7% | 18.1% | 1.99 | -4.7% |
| Real Estate (VNQ) | 12.8% | 13.4% | 0.65 | 23.1% |
| Bitcoin (BTCUSD) | -19.6% | 42.1% | -0.40 | -0.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KVUE | |
|---|---|---|---|---|
| KVUE | -6.7% | 28.8% | -0.41 | - |
| Sector ETF (XLP) | 6.3% | 13.2% | 0.26 | 44.3% |
| Equity (SPY) | 13.1% | 17.1% | 0.60 | 15.7% |
| Gold (GLD) | 20.1% | 17.8% | 0.92 | 2.4% |
| Commodities (DBC) | 14.6% | 19.1% | 0.63 | 0.1% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 25.4% |
| Bitcoin (BTCUSD) | 8.1% | 56.2% | 0.36 | 3.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KVUE | |
|---|---|---|---|---|
| KVUE | -3.4% | 28.8% | -0.41 | - |
| Sector ETF (XLP) | 7.5% | 14.7% | 0.38 | 44.3% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 15.7% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 2.4% |
| Commodities (DBC) | 9.6% | 17.7% | 0.45 | 0.1% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 25.4% |
| Bitcoin (BTCUSD) | 67.5% | 66.9% | 1.07 | 3.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/17/2026 | 2.6% | 3.3% | -4.9% |
| 11/3/2025 | 12.3% | 17.5% | 19.6% |
| 8/7/2025 | 1.5% | 2.2% | -12.3% |
| 5/8/2025 | 4.1% | 1.3% | -5.1% |
| 2/6/2025 | -4.5% | 2.1% | 14.0% |
| 11/7/2024 | 2.1% | 3.7% | 2.4% |
| 8/6/2024 | 14.7% | 15.9% | 24.9% |
| 5/7/2024 | 6.4% | 7.8% | 0.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 6 |
| # Negative | 4 | 3 | 5 |
| Median Positive | 4.1% | 3.5% | 8.3% |
| Median Negative | -4.9% | -4.3% | -5.1% |
| Max Positive | 14.7% | 17.5% | 24.9% |
| Max Negative | -5.8% | -6.0% | -12.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/20/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/24/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 06/02/2023 | 10-Q |
| 12/31/2022 | 05/04/2023 | 424B4 |
| 09/30/2022 | 02/03/2023 | S-1/A |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.